Ambrx, Inc.

Eli Lilly and Company

Metabasis Therapeutics, Inc.

The Scripps Research Institute

Amerx, Inc.

Feng Tian

Anna-Maria A Hays Putnam

Stephanie Chu

Joseph Sheffer

Thea Norman

Ho Sung Cho

Denise Krawitz

Richard Dennis DiMarchi

Zhenwei Miao

Richard Spence Barnett

Peter Connor Canning

Darin Lee

Kyle Atkinson

Marc Siladi

Frank Song

Mark D Erion

Qun Dang

Brett C Bookser

Nicholas Brian Raffaele

Md Harunur Rashid

Brad Hehli

G Sridhar Prasad

Wenyu Li

Peter G Schultz

Troy Edward Wilson

Ying Sun

Nick Knudsen

Anna-Maria A Hays

Thomas O Daniel

Bruce E Kimmel

Thomas P Cujec

Meng-Lin Tsao

Lillian Ho

Marco Gymnopoulos

Sigeng Chen

Vadim Kraynov

William Brady

Ying Buechler

Lillian Skidmore

Bee-Cheng Sim

Jianing Wang

Nickolas Knudsen

Andrew Beck

Michael Deguzman

Harun Rashid

Yingchun Lu

Mark Shimazu

Jinming Xia

Shivarupam Bhowmik

Sung Ju Moon

Disclosed herein are methods, compositions and components for optimizing or increasing expression of a protein, polypeptide or fragment therefrom.

Method for optimizing antibody expression

Described herein are novel anti-CD3 Folate antibodies and uses thereof in the treatment of diseases or conditions that would benefit from such.

Anti-CD3 antibody folate bioconjugates and their uses

The invention relates to prostate specific membrane antigen humanized antibodies (anti-PSMA) and anti-PSMA antibody drug conjugates. The invention also relates to methods and compositions for using anti-PSMA antibody drug conjugates in inhibiting, preventing or treating PSMA related diseases or cancers.

Humanized anti-prostate -specific membrane antigen (PSMA) antibody drug conjugates

The present invention provides methods for targeting interleukin-2 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using an interleukin-2 (IL-2) variant conjugated to a biologically active molecule that will affect cells expressing the interleukin-2 receptor.

Interleukin-2 polypeptide conjugates and their uses

Described herein are novel anti-CD3 antibodies conjugated to folate and uses thereof treatment of diseases or conditions that would benefit from such conjugate are provided.

Anti-CD3-folate conjugates and their uses

Disclosed herein are methods and compositions for generation of cell lines to promote unnatural amino acid-containing protein production using genome engineering technology.

Methods and compositions for promoting non-natural amino acid-containing protein production

This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are &#x3b1;PSMA antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the &#x3b1;PSMA antibodies of the invention are conjugated to one or more toxins. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, dolastatin analogs, and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.

Prostate-specific membrane antigen antibody drug conjugates

Compositions and methods of producing vaccines, including methods wherein whole organism vaccines are provided with limited replication abilities, thereby increasing vaccine safety and efficacy, through the use of non-natural, unnatural, or non-naturally encoded amino acids.

Non-natural amino acid replication-dependent microorganisms and vaccines

The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

Activators of glucokinase

This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in vertebrate cells. The components include orthogonal tRNA's, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNA's/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in vertebrate cells are also provided. The present invention provides vertebrate cells with translation components, e.g., pairs of orthogonal aminoacyl-tRNA synthetases (O-RSs) and orthogonal tRNA's (O-tRNA's) and individual components thereof, that are used in vertebrate protein biosynthetic machinery to incorporate an unnatural amino acid in a growing polypeptide chain, in a vertebrate cell.

Hybrid suppressor tRNA for vertebrate cells

Modified animal erythropoietin polypeptides and uses thereof are provided.

Modified animal erythropoietin polypeptides and their uses

Disclosed herein are methods of detecting non-natural amino acids and polypeptides that include at least one non-natural amino acid. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of functionalities, including but not limited to oxime, carbonyl, and/or hydroxylamine groups. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, and methods for detecting such polypeptides.

Methods and compositions comprising non-natural amino acids

Novel antigen-binding polypeptides (ABP) and uses thereof are provided.

Antigen-binding polypeptides and their uses

Growing community of inventors

San Diego, CA, United States of America

Feng Tian